The performance of MALAT1 alone was not inferior to that of clinical stage and HBsAg in the prediction of progression, or from that of tumor size and HBsAg in the prediction of survival when data were censored at > 40 months (Figures 14C, D). The gene discussed is MALAT1; the disease is neoplasm.